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Abstract
Purpose GPA33 is a colorectal cancer (CRC) antigen with
unique retention properties after huA33-mediated tumor
targeting. We tested a pretargeted radioimmunotherapy
(PRIT) approach for CRC using a tetravalent bispecific anti-
body with dual specificity for GPA33 tumor antigen and
DOTA-Bn–(radiolanthanide metal) complex.
Methods PRIT was optimized in vivo by titrating sequential
intravenous doses of huA33-C825, the dextran-based clearing
agent, and the C825 haptens 177Lu-or 86Y-DOTA-Bn in mice
bearing the SW1222 subcutaneous (s.c.) CRC xenograft
model.
Results Using optimized PRIT, therapeutic indices (TIs) for
tumor radiation-absorbed dose of 73 (tumor/blood) and 12
(tumor/kidney) were achieved. Estimated absorbed doses
(cGy/MBq) to tumor, blood, liver, spleen, and kidney for
single-cycle PRIT were 65.8, 0.9 (TI 73), 6.3 (TI 10), 6.6
(TI 10), and 5.3 (TI 12), respectively. Two cycles of PRIT
(66.6 or 111 MBq 177Lu-DOTA-Bn) were safe and effective,
with a complete response of established s.c. tumors
(100 – 700 mm3) in nine of nine mice, with two mice alive
without recurrence at >140 days. Tumor log kill in this model
was estimated to be 2.1 – 3.0 based on time to 500-mm3 tumor
recurrence. In addition, PRIT dosimetry/diagnosis was per-
formed by PET imaging of the positron-emitting DOTA hap-
ten 86Y-DOTA-Bn.
Conclusion We have developed anti-GPA33 PRIT as a triple-
step theranostic strategy for preclinical detection, dosimetry,
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and safe targeted radiotherapy of established human colorectal
mouse xenografts.
Keywords Multistep targeting . Bispecific antibodies .
GPA33 . Radioimmunotherapy . Pretargeting
Introduction
Despite therapeutic advances in the last decade, colorectal
cancer (CRC) is still the fourth leading cause of death world-
wide, and 49,700 CRC deaths are projected for 2015 in the US
alone [1]. Although locoregional therapies such as surgery and
radiation can be curative in many cases, these approaches do
not control tumors that have metastasized at diagnosis, for
which chemotherapy and targeted small molecules are most
often palliative, with rapid development of resistance. Clearly,
there is an unmet need for improved therapeutics, particularly
for the treatment of unresectable metastatic disease. In princi-
ple, targeted radiation therapy strategies such as
radioimmunotherapy (RIT) could potentially address this un-
met need, because they enable delivery of tumoricidal radia-
tion doses to multiple systemically dispersed sites simulta-
neously (e.g., ranging from macroscopic nodal or hepatic
oligometastases to occult micrometastatic disease) as long as
the therapeutic indices (TIs) are favorable [2]. Notably, the
majority of RIT trials in CRC have been with IgGs directed
at carcinoembryonic antigen (CEA) (e.g., 131I-hMN-14 [3]
and 90Y-cT84.66 [4]). So far, these studies have had only
limited clinical success because of suboptimal TIs of only
5 – 10:1 for macroscopic tumors, which is inadequate for
curative therapy without dose-limiting hematologic toxicity.
Since particularly radioresistant solid tumors such as CRC
may require a total absorbed dose of 7,000 – 10,000 cGy for
cure, we need highly selective tumor targeting with respect to
radiosensitive normal tissues (typically bone marrow, which
may be suppressed by doses as low as 150 cGy). The RIT
approach that offers the greatest potential for improving TI
is the pretargeted approach (PRIT) utilizing bispecific anti-
bodies (BsAb) [5]. For small-volume or microscopic disease,
there is evidence that uptake, and consequently TI, may be
higher in both animal models [6, 7] and human patients [8, 9].
This, taken in conjunction with the reduced tumor cell number
in such small tumors, means that the likelihood of achieving
complete ablation can be expected to be greater than in mac-
roscopic disease, as long as a radionuclide appropriate for
small-volume disease is used [10]. However, in the most gen-
eral case, small-volume disease will coexist with macroscopic
disease in the same patient and treatment approaches are re-
quired that address the entire disease spectrum. Moreover, if
PRIT can improve the treatment of macroscopic disease, it
will concomitantly improve that of microscopic disease by
the same mechanisms and at no additional cost.
PRIT, a concept that separates the delivery of the targeting
antibody to tumor from the delivery of the radioactivity, was
initially developed by Reardan et al. [11], Goodwin et al. [12],
and Feng et al. [13] using anti-radiometal chelate antibodies.
The initial uptake studies demonstrated the proof of principle
for this approach, showing improved tumor targeting com-
pared to conventional RIT, but TIs were still suboptimal, part-
ly because of the insufficient retention (on the order of several
hours) of the radioactivity when carried by anti-chelate anti-
bodies of only nanomolar aff ini ty [14, 15]. The
BsAb/radiometal binding approach took a major step forward
with the development of ultra-high affinity antibodies for the
radiometal–chelate binding step, based on the work of Orcutt
et al. [16] at the Massachusetts Institute of Technology (MIT).
Guided by a mathematical modeling approach that predicted
the optimal required affinity of the hapten antibody binding
step in PRIT, theMIT team, using directed evolution and yeast
surface display, was able to affinity mature by more than
1000-fold to the low picomolar range the original 2D12.5
antibody specific for the benzyl(Bn)-DOTA–metal complex,
now reformatted as the BC825^ single-chain variable fragment
(scFv) [16]. Next, the MIT team engineered BsAbs incorpo-
rating the C825 sequence utilizing a highly modular IgG-scFv
scaffold (e.g., anti-CEA/C825) [17]. These IgG-scFv antibody
compositions are tetravalent molecules, consisting of two
binding sites for tumor antigen (typically, about 10 nM), and
two binding sites for the Bn-DOTA-radiometal hapten (about
10 – 20 pM).
We recently adopted this methodology for PRIT by focus-
ing on anti-GD2 antibodies with a documented record of safe
use and proven tumor localization in humans [18]. For CRC,
we reasoned that the GPA33 target could be ideal for PRIT.
GPA33 is a transmembrane glycoprotein abundantly
expressed in over 95 % of CRCs, with restricted expression
in normal tissue (colon and bowel epithelium) [19]. It exhibits
long-term residence in cell membrane in tumors, relative to
intestine, with minimal internalization and minimal vascular
shedding. Using a variety of radiolabeled antibody forms, in-
cluding initially a murine monoclonal antibody (A33 [20])
and subsequently a humanized version (huA33 [21]), this an-
tigen is one of the most extensively studied targets in vivo. For
example, we have performed 124I-huA33 imaging in patients
with CRC and confirmed through kinetic modeling that the
differential clearance between antigen-positive tumor and
antigen-positive intestine would yield TIs sufficient for tumor
response to PRIT [8, 22, 23].
As we developed PRIT, the need for radiation dosimetry
based on quantitative imaging for measurement of time-
dependent activity distribution in tumor and normal tissues
for optimal translation of PRIT to humans became apparent.
Combined therapeutic and diagnostic, or Btheranostic,^ PRIT
refers to the use of reagents with virtually identical chemistries
as vehicles for both diagnostic and therapeutic applications.
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We have previously described successful applications of this
approach using PET imaging of 124I as a surrogate for 131I
therapy in thyroid cancer [24–26]. In the present studies, we
applied 177Lu as both the therapeutic (β-emission for RIT) and
diagnostic (γ-emission for imaging) radionuclide, and 177Lu
itself, and 86Y as its diagnostic surrogate. Furthermore, we
emphasized 177Lu because the lower β-emission energy and
short path length make it more likely to eradicate small tu-
mors, in comparison to a longer β-emission path length radio-
nuclide such as 90Y.
In the study reported here, we tested the principal hypoth-
esis that optimized theranostic PRIT based on GPA33 antigen
tumor targeting and a BsAb-huA33 construct can be used to
achieve the high TIs required for effective and safe CRC ther-
apy in xenografts in mice and, ultimately, in humans.
Materials and methods
Cloning and expression of huA33-C825
HuA33-C825 was prepared using the sequences for huA33
[21] and C825 [16], a murine scFv antibody with high affinity
for DOTA–radiometal complexes (Fig. 1a). The BsAb was
made using the same platform as control hu3F8-C825 [18],
only replacing variable regions (VH and VL) of hu3F8 with
those of huA33 [21]. The IgG-scFv BsAb (molecular weight
about 210 kDa) was produced in CHO cells and purified by
protein A affinity chromatography as previously described
[18].
Surface plasmon resonance studies
A Biacore T100 biosensor, a CM5 sensor chip, and related
reagents were purchased from GE Healthcare. The human
GPA33 recombinant protein was purchased from
Novoprotein. A BSA-(Y)-DOTA-Bn conjugate was prepared
as previously described [18]. Both antigens were immobilized
using the amine coupling kit (GE Healthcare). Purified BsAbs
and control antibodies were analyzed and data fit to a bivalent
analyte model using the Biacore T100 evaluation software as
previously described [18].
Anti-GPA33 PRIT reagents, protocol, and xenograft
studies
The GPA33(+) human CRC cell line SW1222 was obtained
from the Ludwig Institute for Cancer Immunotherapy (New
York, NY). SW1222 is notable among commonly investigated
human CRC cell lines for preclinical RIT [27–30] in that it
forms relatively well-differentiated and highly vascular sub-
cutaneous (s.c.) tumors and is thus well-suited to antibody
targeting [31]. 131I-A33 was used to demonstrate that a dose
of 68 Gy to SW1222 tumors resulted in cures [29]. Details
regarding the culturing of SW1222 and inoculation into im-
munocompromised mice are provided in the Supplementary
material. Established tumors (50 – 700mm3) were observed in
7 – 10 days; tumor volumes (TVs) were estimated using the
formula for the volume (V) of an ellipsoid: V=4/3π(length/2×
width/2×height/2), with dimensions in millimeters. All re-
agents were administered intravenously via a lateral tail vein.
The anti-GPA33 PRIT protocol included injections of the
following three reagents. HuA33-C825 BsAb (0.25 mg,
1.19 nmol) was injected first to allow localization in the tumor
(t=−28 h). At t=−4 h 24 h later circulating BsAb was cleared
by injection of a clearing agent (CA; 62.5 μg, 0.125 nmol)
comprising a 500-kDa dextran-(Y)-DOTA-Bn conjugate pre-
pared as previously described by Orcutt et al. [32]
and formulated in saline for injection (7.625 nmol of (Y)-
DOTA-Bn). Finally, 4 h after injection of CA, the 177Lu-
DOTA-Bn was injected (t=0 h). Radiolabeled DOTA-Bn
was prepared as previously described [18] by incubating
DOTA-Bn (p-NH2-Bn-DOTA, molecular weight 655 Da;
Macrocyclics) and 177Lu (carrier-added, specific activity
about 1,110 GBq/mg; Perkin Elmer) or 86Y (carrier-free, spe-
cific activity about 1,110 GBq/mg; Radiological Chemistry
and Imaging Laboratory at Washington University in St.
Louis) at 80 °C for 1 h, and formulated in saline for injection
(the PRIT strategy is shown in Supplementary Fig. 1).
Micro single-photon emission computed tomography inte-
grated with X-ray computed tomography (X-SPECT/CT) im-
aging was performed on selected mice during PRIT optimiza-
tion. In addition, separate biodistribution studies were con-
ducted with huA33-C825 trace radiolabeled with 131I
(Nordion) to estimate tumor uptake during PRIT (i.e., at
24 h post-injection, p.i.). Details regarding X-SPECT/CT im-
aging, tracer preparation and quality control, as well as the
ex vivo biodistribution analysis of radioactivity following ra-
diotracer injection are provided in the Supplementary
material.
PET imaging of anti-GPA33 PRIT + 86Y-DOTA-Bn
A single group of five mice bearing GPA33(+) SW1222 tu-
mors in the shoulder were given PRIT (as described above)
using 8.6 – 8.8 MBq (about 50 pmol) of 86Y-DOTA-Bn, and
noninvasively imaged at approximately 2 and 20 h p.i. using a
microPET Focus 120 (CTI Molecular Imaging, Inc.,
Knoxville, TN) and previously described methods [33]. A
detailed description of the imaging protocol is provided in
the Supplementary material.
Estimation of absorbed doses
Groups of GPA33(+) SW1222 tumor-bearing mice (n=4 or 5)
were given PRIT + 1.85 – 2.0 MBq (about 10 pmol) of 177Lu-
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DOTA-Bn and sacrificed at 2 h (n=5), 24 h (n=4), and 120 h
(n=5) p.i. for biodistribution analysis of 177Lu activity in tumor
and selected normal tissues. Details regarding calculation of
estimated absorbed doses are provided in the Supplementary
material.
Titration of administered 177Lu-DOTA-Bn activity
following PRITwith optimized BsAb and CA doses
To determine the effect of the 177Lu-DOTA-Bn dose on the
relative uptake of 177Lu-DOTA-Bn in tumor and kidney dur-
ing PRIT, groups of tumor-bearing mice (n=5 per group) were
given PRIT + 11.1 MBq (11.1 – 11.4; 60 pmol), 55.5 MBq
(54.6 – 55.1; 300 pmol), or 111.0 MBq (109.5 – 112.5 MBq;
600 pmol) of 177Lu-DOTA-Bn. All mice were sacrificed at 24 h
p.i. of 177Lu-DOTA-Bn for biodistribution analysis of 177Lu
activity. These data were plotted in combination with the
PRIT + 1.85 – 2.0 MBq (about 10 pmol) biodistribution data
of 177Lu activity in tumor and kidney to estimate tissue satura-
tion of 177Lu-DOTA-Bn during PRIT. In addition to the quan-
tification of activity by gamma counting, the kidneys were
collected from animals given PRIT + 11.1 – 111.0 MBq and
frozen at −80 °C in OCT for autoradiography and histochem-
istry analysis. A detailed description of the autoradiography and
histochemistry protocol is provided in the Supplementary
material.
Theranostic 177Lu-DOTA-Bn treatment using optimized
PRIT strategy
Groups of SW1222 tumor-bearing mice (50 – 150 mm3) were
injected with either huA33-C825 or nonspecific IgG-C825
PRIT (i.e., single-cycle treatment; BsAb injection on day 6
and CA/177Lu-DOTA-Bn injections on day 7 after tumor in-
oculation) or two cycles of PRIT (i.e., fractionated treatment;
BsAb injections on days 9 and 16 and CA/177Lu-DOTA-Bn
Fig. 1 a Structure of M-DOTA-Bn and C825 scFv affinities for either Y-
DOTA-Bn or Lu-DOTA-Bn as reported by Orcutt et al. [16]. bX-SPECT/
CT maximum intensity projection images of the same mouse bearing a
SW1222 tumor 2 h (left) and 20 h (right) following anti-GPA33 PRIT
with 177Lu-DOTA-Bn. The following were administered for PRIT:
0.1 mg of BsAb, 40 μg of clearing agent, and 7.4 MBq 177Lu-DOTA-
Bn. c Decay-corrected 177Lu activity biodistribution curves for SW1222
tumor as well as selected normal tissues from 2 to 120 h after injection
following huA33-C825 PRIT + 177Lu-DOTA-Bn (1.85 – 2.0MBq, about
10 pmol). d Representative noninvasive serial PET images of the same
nude mouse bearing a subcutaneous SW1222 tumor in the shoulder
(arrows) at 2 and 20 h after injection of huA33-C825 PRIT + 86Y-
DOTA-Bn (8.6 – 8.8 MBq, about 50 pmol). Transverse and coronal
slices through the tumor are shown. The images have been corrected for
decay to the time of injection and calibrated for quantitation of activity in
regions of interest and scaled to the same intensity
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injections on days 10 and 17 after tumor inoculation). For
PRIT with nonspecific IgG-C825, an equivalent milligram
dose of the GD2-targeted BsAb hu3F8-C825 [18] was used
in place of huA33-C825, since it does not cross-react with
SW1222 tumor. TVs were measured three times a week and
the following definitions were used to describe treatment re-
sponse: a complete response (CR) was defined as tumor
shrinkage to 20 % of initial TV during treatment; a partial
response (PR) was defined as a tumor showing no change in
growth between successive measurements or any other tumor
shrinkage not considered a CR; and an excessive tumor bur-
den was defined as a final TVof >2,000 mm3.
Treated mice underwent noninvasive planar scintigraphy
at 20 h p.i. of 177Lu-DOTA-Bn (details of the imaging method
are provided in the Supplementary material) to verify tumor-
specific versus nonspecific targeting as well as to assess
whole-body clearance in mice receiving 177Lu-DOTA-Bn
alone [34]. Animals were observed until they were sacrificed
due to excessive tumor burden (unless otherwise noted).
Animals showing a weight loss greater than 15% of their initial
body weight in 1 or 2 days, or 20 % or more of their starting
weight, were removed from the group at that time and
sacrificed. To further evaluate toxicity, a total of eight randomly
selected animals undergoing treatment were submitted for his-
topathologic assessment of the site of s.c. tumor, and assess-
ment of the kidney, bone marrow (sternum, vertebrae, femur,
and tibia), liver, and spleen by board-certified pathologists at
the Memorial Sloan Kettering Cancer Center Laboratory of
Comparative Pathology. Immunohistochemical (IHC) staining
for the presence of GPA33 was also carried out in these mice
using previously described protocols [8]. The maximum toler-
ated dose (MTD) was not determined in this study.
Results
In vitro characterization of huA33-C825
Biochemical purity analysis of huA33-C825 by size-
exclusion high-pressure liquid chromatography (SE-HPLC)
is shown in Supplementary Fig. 2a. SE-HPLC showed amajor
peak (90 % by UV analysis) with an approximate molecular
weight of 210 kDa, as well as some minor peaks assumed to
be aggregates removable by gel filtration. The BsAb remained
stable by SE-HPLC and Biacore after multiple freeze and
thaw cycles (data not shown). The binding affinity was mea-
sured by Biacore T100. For GPA33, huA33-C825 had a kon of
9.15×104 M−1s−1, a koff of 5.81×10
−3 s−1, and an overall KD
of 63.5 nM—less than the parental huA33-IgG1 values (kon
6.14×105M−1s−1, koff 1.05×10
−3s−1, and overallKD 1.71 nM;
Supplementary Fig. 2b). For antigen BSA-(Y)-DOTA-Bn,
huA33-C825 had a kon of 1.90×10
4 M−1s−1, a koff of 2.20×
10−4 s−1, and an overall KD of 11.6 nM—comparable to the
control IgG-C825 values (the anti-GD2 BsAb hu3F8-C825;
kon 1.60×10
4 M−1s−1, koff 3.37×10
−4 s−1, and overall KD
21.2 nM; Supplementary Fig. 2c). In summary, huA33-C825
retained high binding affinity to BSA-(Y)-DOTA-Bn, but lost
considerable affinity to antigen GPA33.
Optimization of PRITwith huA33-C825, CA,
and 177Lu-DOTA-Bn
A combination of X-SPECT/CT imaging and ex vivo
biodistribution studies of huA33-C825 PRIT + 177Lu-
DOTA-Bn were used to optimize huA33-C825 and CA doses
during PRIT with the aims of achieving high uptake by the
tumor while simultaneouslyminimizing exposure of radiosen-
sitive normal organs such as the blood and kidney (see
Supplementary Fig. 3). A representative X-SPECT/CT image
following PRIT + 177Lu-DOTA-Bn targeting of GPA33(+) to
a SW1222 xenograft in vivo is shown in Fig. 1b. The 131I-
huA33-C825 uptake in tumor at 24 h p.i. (average±standard
deviation, SD) was 3.71±1.00 %ID/g (activity values are
shown in Supplementary Table 2). Taking into account the
tracer-specific activity and dose, this corresponds to an abso-
lute huA33-C825 uptake of 44 pmol/g (with about 50 % IR,
then 88 pmol/g).
Absorbed dose estimates for optimized PRIT +
177Lu-DOTA-Bn
Decay-corrected time-activity curves up to 120 h p.i. of
177Lu-DOTA-Bn for tumor, kidneys, liver, spleen, and blood
are shown in Fig. 1c (activity values are shown in
Supplementary Table 1). The estimated absorbed doses of
177Lu-DOTA-Bn for blood, tumor, liver, spleen, and kidneys
were 0.9, 65.8, 6.3, 6.6, and 5.3 cGy/MBq, respectively
(Table 1). The ratio of absorbed dose estimates for tumor to
those for selected normal tissues (i.e., TI) ranged from about
10 (e.g., for liver, spleen, and kidney) to about 220 for muscle
(Table 1).
Serial noninvasive PET imaging of GPA33(+) xenografts
with PRIT + 86Y-DOTA-Bn
Representative PET images of SW1222 tumor-bearingmice at
2 and 20 h p.i. of PRIT + 86Y-DOTA-Bn are shown in Fig. 1d.
The correspondingmaximum intensity projection PET images
are provided in Supplementary Fig. 4. The CRC xenograft in
the shoulder can be clearly delineated with minimal uptake in
normal tissue and thus high overall contrast. The uptake in
tumor was quantified by region-of-interest analysis of each
of the calibrated PET images, and was determined to be
8.75±0.91 and 8.44±1.01 %ID/g (average±standard error of
the mean, SEM; n=5) at 2 and 20 h p.i., respectively, indicat-
ing rapid uptake of 86Y-DOTA-Bn (presumably by tumor-
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associated huA33-C825) and slow subsequent clearance of
the huA33-C825/86Y-DOTA-Bn complex from the tumor.
The tumor uptake determined by ex vivo biodistribution at
24 h p.i. was 7.85±0.65 %ID/g. A comparison of the tumor
uptake determined by either PET imaging or biodistribution of
PRIT with either 86Y-DOTA-Bn or 177Lu-DOTA-Bn at 2 and
24 h p.i. is shown in Supplementary Fig. 5. No significant
difference (P>0.05) was observed between the two isotopes
at either time point, suggesting good correlation between the
in vivo fates of the two distinct M-DOTA-Bn haptens follow-
ing PRIT.
Titration of 177Lu-DOTA-Bn administered activity
during PRIT
The uptake in tumor and kidney at 24 h p.i. (as %ID/g, aver-
age±SD) as a function of administered 177Lu-DOTA-Bn ac-
tivity ranging from about 2.0 to 111.0MBq is shown in Fig. 2a.
While the relative 177Lu activity decreased about four-fold for
tumor with increasing administered activity (e.g., about 8.5 to
2 % ID/g for 2.0 MBq and 111.0 MBq, respectively), the rela-
tive 177Lu activity in kidney remained <1 % ID/g and relatively
constant (average range 0.46 – 0.96 %ID/g), suggesting that
saturation of available specific M-DOTA-Bn receptors by
hapten was occurring in the tumor but not in the kidney com-
partments. The absolute 177Lu activity uptake in tumor is
shown in Fig. 2b, and was fitted to a one-phase association
equation (GraphPad Prism version 6.00), with saturation appar-
ent at a 177Lu-DOTA-Bn activity of about 11 pmol/g of tumor
(R2=0.89). Thus, during PRIT studies, 177Lu-DOTA-Bn
activities ≤55.0 MBq were considered subsaturating.
Representative autoradiography and histochemistry data for
kidney for three different 177Lu-DOTA-Bn activity levels
(11.1, 55.5, and 111.0 MBq) are shown in Fig. 2c. The
177Lu activity appeared to be distributed predominantly in
the renal cortex, with the cortex-to-medulla activity concen-
tration ratios increasing with increases in administered 177Lu-
DOTA-Bn activity.
PRIT studies
A total of three separate therapy studies with 177Lu-DOTA-Bn
were conducted in SW1222 tumor-bearing mice to evaluate
efficacy. A summary of all tumor response data as well as
estimated absorbed doses for tumor, blood, and kidney for
all PRIT groups is provided in Table 2. No significant weight
loss was observed in any of the control or treatment groups
(data not shown).
Fig. 2 a 177Lu activities in tumor and kidney determined by ex vivo
biodistribution for anti-GPA33 PRIT + 177Lu-DOTA-Bn doses ranging
from about 2.0 to 111.0MBq. bAbsolute 177Lu activity in tumor for anti-
GPA33 PRIT + 177Lu-DOTA-Bn doses ranging from about 2.0 to 111.0
MBq. c Representative ex vivo autoradiograms (Autorad.) and IHC
(H&E) images of kidney following anti-GPA33 PRIT + three different
177Lu-DOTA-Bn administered activities at 24 h p.i.
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First, five groups of tumor-bearing mice (n=6 – 8 per
group; 7-day old tumors, TV 100 – 200 mm3) were treated
with: either vehicle alone (i.e., untreated, n=8), 33.3 MBq
177Lu-DOTA-Bn alone (vehicle given during BsAb and CA
injections, n=6), nonspecific hu3F8-C825 PRIT + 33.3 MBq
177Lu-DOTA-Bn (control antibody, n=8), or huA33-C825
PRIT + either 11.1 MBq or 33.3 MBq 177Lu-DOTA-Bn (an-
tibody of interest, both n=8). Tumor response data from treat-
ment groups are shown in Fig. 3 and Supplementary Fig. 6.
Representative scintigraphy images of selected treated mice
are shown in Supplementary Fig. 7 and confirm specific tumor
targeting during PRIT including huA33-C825 and 177Lu-
DOTA-Bn compared with controls and nonspecific PRIT. To
summarize efficacy, no CRs were seen in any of the GPA33-
targeted PRIT or control groups. Also, unremarkable PRs
(slight tumor growth delays) were seen only in groups treated
with huA33-C825 PRIT + 177Lu-DOTA-Bn administered ac-
tivity up to 33.3 MBq.
1 x 33.3 MBq 177Lu-DOTA-Bn only (no BsAb; total 33.3 MBq) 1 x huA33-C825 PRIT + 33.3 MBq (total: 33.3 MBq)
a
Control (no treatment)
b
1 x IgG-C825 PRIT + 33.3 MBq (total: 33.3 MBq)
c
d
Fig. 3 Tumor response data for therapy studies including: a control (no
treatment), b single-cycle treatment with 177Lu-DOTA-Bn only (i.e., no
BsAb or CA; 177Lu-DOTA-Bn administered activity 33.3 MBq), c
Nonspecific hu3F8-C825 (i.e., IgG-C825) PRIT (177Lu-DOTA-Bn ad-
ministered activity 33.3 MBq), and d anti-GPA33 PRIT (177Lu-DOTA-
Bn administered activity 33.3 MBq). Blue line indicates average values
Table 1 Absorbed doses for anti-GPA33 PRIT with 177Lu-DOTA-Bn
in nude mice carrying s.c. GPA33(+) SW1222 tumors
Tissue Absorbed dose
(cGy/MBq)
Therapeutic
index
Blood 0.9 73
Tumor 65.8 –
Heart 1.4 47
Lung 1.8 37
Liver 6.3 10
Spleen 6.6 10
Stomach 0.6 110
Small Intestine 0.5 132
Large Intestine 0.8 82
Kidneys 5.3 12
Muscle 0.3 219
Bone 0.6 110
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In the second therapy study, a two-cycle regimen of
huA33-C825 PRIT was investigated (n=4 or 5 per group;
10-day old tumors, TV 200 – 700 mm3). Similar to the
first treatment study, the five untreated mice had to be
sacrificed within 30 days due to excessive tumor burden,
and the time to reach 500 mm3 was 13±2 days (data not
shown). Two of five animals treated with 2 × huA33-
C825 PRIT+11.1 MBq 177Lu-DOTA-Bn (total 177Lu-
DOTA-Bn administered activity 22.2 MBq; estimated tu-
mor absorbed dose 15 Gy) showed CR (Fig. 4a). In the
animals with recurrent tumors, the time to reach 500 mm3
was 9 or 36 days. Five of five animals treated with 2 ×
huA33-C825 PRIT + 33.3 MBq 177Lu-DOTA-Bn (total
177Lu-DOTA-Bn administered activity 66.6 MBq; estimated
tumor absorbed dose 44 Gy) showed CR (Fig. 4b). In the
animals with recurrent tumors, the time to reach 500 mm3
was 7, 12, 23, and 65 days (average 27±26 days), and a single
mouse showed a tumor size of <10 mm3 at 140 days. Four of
four mice treated with two cycles of huA33-C825 PRIT +
55.5 MBq 177Lu-DOTA-Bn (total 177Lu-DOTA-Bn adminis-
tered activity 111.0 MBq; estimated tumor absorbed dose
73 Gy) showed CR (Fig. 4c, left). In the animals with recur-
rent tumors, the time to reach 500 mm3 was 34, 42, and
45 days (average 40±6 days), and a single mouse had a tumor
size of 44 mm3 at 140 days. No major treatment-related tox-
icities were observed in eight of eight mice randomly selected
for necropsy and pathologic assessment (pathologist summary
provided in the Supplementary material). In addition, IHC
staining of the tumor sections revealed that the residual tumor
was GPA33-positive (Fig. 4d).
Following these PRIT studies, we made some very approx-
imate estimates of the number of clonogenic tumor cells
remaining per mouse after dual-cycle treatment with
huA33-C825 PRIT + 55.5 MBq 177Lu-DOTA-Bn. We noted
that the individual tumors that responded to treatment with a
CR or greater dropped below the detection (palpation)
threshold at about 12 days after the second treatment dose,
or at about 30 days after inoculation of tumor cells (Fig. 4c).
This was used as time zero, from which regrowth of
clonogenic cells would begin, to a volume of 500 mm3 (i.e.,
recurrence). The estimated tumor-absorbed dose of 73 Gy
resulted in CRs in four of four mice, including a single
survivor without recurrence at 140 days. Based on an
observed tumor doubling time of 5 days, the three tumors that
recurred at approximately 35, 40, and 45 days (seven to nine
doublings) after the nadir had an implied cell kill of 2 – 3 logs.
For the tumor without visible regrowth during the 140-day
observation period, it was more difficult to estimate a cell kill
because it may or may not have been cured. If the tumor had
recurred at 140 days (28 doublings) after the nadir, the implied
cell kill would have been approximately 8 logs. If we assume
some numerical value for clonogenic cell density, it is possible
to calculate how many logs of cell kill would be required to
produce a significant probability of cure. For example, a
clonogenic cell density of 109 cells per gram would imply that
approximately 9 logs of kill are required to reduce a 500-mg
tumor to a single surviving clonogenic cell. However, if the
true number was 106 cells per gram, then only 6 logs of kill
would be required. These values (and their associated uncer-
tainties) translate into the amount of radiation dose that would
be required to achieve a significant level of tumor cure. If an
estimated tumor dose of 73 Gy gives approximately 3 logs of
kill but 9 logs are needed (i.e., 109 cells/g), then the dose
would have to be three times greater (i.e., 220 Gy). In contrast,
if only 6 logs are needed (i.e., 106 cells/g) then the dose would
need to be two times greater (i.e., 150 Gy). However, if the
true number of clonogenic cells per gram was only 103 (e.g., a
cancer stem cell-like scenario), doses similar to the current
estimated value of 73 Gy would already be sufficiently high
to produce a significant likelihood of tumor cure. Our
experimental observation of a 25 % probability of cure seems
to most closely resemble the last of these scenarios. Of course,
Table 2 Anti-GPA33 PRIT studies with either single-cycle or dual-cycle anti-GPA33 PRIT + 177Lu-DOTA-Bn administered activities up to 111.0 MBq
Anti-GPA33
PRIT
177Lu-DOTA-Bn
administered activity
(MBq)
Tumor-absorbed
dose (cGy)b
Blood-absorbed
dose (cGy)c
Kidney-absorbed
dose (cGy)d
Complete
response
Survival at
140 days
Time to tumor recurrence
500 mm2 (days)
Single-cycle 11.1 730 10 59 0/8 0/8 –
33.3 2,191 30 176 0/8 0/8 –
111.0 2,580a 100 588 2/5 1/5 65
Dual-cycle 2×11.1 (22.2) 1,460 20 118 2/5 0/5 9, 36; median 22.5
2×33.3 (66.6) 4,382 60 354 5/5 1/5 7, 12, 23, 65; median 17.5
2×55.5 (111.0) 7,304 100 588 4/4 1/4 34, 42, 45; median 42
aAdjusted for average tumor uptake of 3 % ID/g at 24 h p.i. to account for saturating dose
b 65.8 cGy/MBq based on average tumor uptake of 8.5 % ID/g at 24 h p.i.
c 0.9 cGy/MBq
d 5.3 cGy/MBq
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in reality, we do not know what the clonogenic tumor cell
density is, and tumor regression and regrowth are likely to
be more complex than a simple monoexponential function,
so these speculative calculations should be considered with
caution.
Finally, a third PRIT study was performed at a 177Lu-
DOTA-Bn dose of 111.0 MBq, administered as a single
cycle to compare treatment with single versus fractionated
PRIT dosing (n=5 per group; 10-day old tumors, TV
50 – 300 mm3). All untreated mice showed similar tumor
growth kinetics to those seen in previous studies (tumor
doubling time about 5 days, data not shown). PRIT pro-
duced PR in three of the five mice as well as CR in two
mice with delayed recurrence in one mouse (the time to
reach 500 mm3 was 65 days) and a single survivor without
recurrence at 140 days (at 140 days after tumor inoculation,
no measurable tumor at the site of s.c. injection; 10-day TV
121 mm3; Fig. 4c, right). A single treated mouse showing a
2 x huA33-C825 PRIT + 55.5 MBq (total: 111.0 MBq)
CR: 4/4
survivors @ 140 d: 1/4
1x huA33-C825 PRIT + 111.0 MBq (total: 111.0 MBq)
PR: 3/5, CR: 2/5
survivors @ 140 d: 1/5
CR: 5/5
survivors @ 140 d: 1/5
2 x huA33-C825 PRIT + 
11.1 MBq (total: 22.2 MBq)
NR: 3/5
CR: 2/5
survivors @ 140 d: 0/5
2 x huA33-C825 PRIT + 
33.3 MBq (total: 66.6 MBq)
H&E
a d
b
c
2x
GPA33+
2x
NR CR, senescence
H&E
40x
GPA33+
40x
*
*
*
*
*
*
Fig 4 Tumor response data for dual-cycle PRIT + (a) 11.1 MBq 177Lu-
DOTA-Bn (total 22.2 MBq), + (b) 33.3 MBq 177Lu-DOTA-Bn (total
66.6 MBq) or + (c, left) 55.5 MBq177Lu-DOTA-Bn (total 111.0 MBq).
Tumor response data for single-cycle PRIT + 111.0 MBq of 177Lu-
DOTA-Bn is also shown (c, right). d Morphologic assessment and IHC
detection of GPA33 antigen in formalin-fixed, paraffin-embedded sec-
tions of tumors from selected GPA33(+) PRIT-treated mice: left
nonresponding (NR) tumor (tumor size at the time of sacrifice
>1,500 mm3) from a mouse treated with 2 × huA33-C825 PRIT +
11.1 MBq (total 22.2 MBq); right tumor with CR showing senescence
at 140 days from a mouse treated with 2 × huA33-C825 PRIT +
55.5 MBq (total 111.0 MBq). Sections of thickness 5 μm were stained
with hematoxylin and eosin (H&E) and immunohistochemically ana-
lyzed with murine monoclonal antibody A33 for the presence of
GPA33 antigen (GPA33+). The NR tumor appears as a bulky mass
displaying little to no necrosis in the solid antigen-positive tumor areas.
High magnification shows large intact tumor cells without necrotic
changes. The CR senescent tumor is considerably smaller (about
40mm3 at the time of sacrifice at 140 days) than the NR tumor and shows
large necrotic areas (asterisk) in the center with surrounding partially
papillary-shaped vital tumor formations. High magnification shows a
papillary tumor area with a central stroma core and surrounding
GPA33-positive necrotic areas
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PR had to be sacrificed due to mobility concerns (unrelated
to treatment) 18 days after treatment.
Discussion
We achieved our goal of demonstrating that a dosimetry-based
TI could be used as a benchmark for successful therapeutic
targeting by PRIT in CRC. We demonstrated mean TIs of
about 73 for blood and 12 for kidney, and an estimated tumor
dose of 43 – 73 Gy with an estimated 2.1 – 3.0 log kill at a 73-
Gy tumor-absorbed dose, without detectable bone marrow
and renal toxicity. We used 177Lu-DOTA-Bn for theranostic
RITwith administered activities up to 111.0 MBq delivered in
a fractionated dose strategy (e.g., 2 × huA33-C825 PRIT +
55.5 MBq) to produce CR with 100 % frequency, including
survival beyond 140 days in two of nine mice, with no major
treatment-related toxicities observed. IHC analysis of the re-
sidual tumors revealed a GPA33(+) phenotype, suggesting
that the reason for recurrence of some tumors was insufficient
tumor-absorbed dose rather than escape by genetic mutation
or some other mechanism.We also found that PRIT is a highly
flexible approach that is readily adaptable to multiple dosing
regimens, and in fact divided doses were more effective than
equivalent single doses in inducing CR. Based on the absence
of any treatment-related toxicities, all of our therapeutic regi-
mens delivered normal-tissue absorbed doses well below the
respective normal-tissue MTDs. Dose escalation could there-
fore safely proceed in this setting.
At the MTD, we anticipate that the normal tissues most
sensitive to off-target radiotoxicity during anti-GPA33 PRIT
would be bone marrow (using blood as a dosimetric surrogate
for bone marrow), lung, liver, and kidneys (estimated absorbed
doses 0.9, 1.8, 6.3, and 5.3 cGy/MBq, respectively; Table 1).
Based on human normal-tissue radiation dose tolerance
estimates derived from clinical observations [35], the MTDs
are 250 cGy for bone marrow, 1,500 cGy for lung, 3,000 cGy
for liver, and 2,000 cGy for kidney. Therefore, we estimate that
the maximum tolerated pretargeted 177Lu-DOTA-Bn activity is
278 MBq, with the bone marrow as the dose-limiting organ. At
this activity, the estimated absorbed dose delivered to tumor
would be 18,292 cGy (183 Gy), with 250 cGy to blood
(marrow) and 1,473 cGy to kidney.
We demonstrated that serial, noninvasive X-SPECT/CT
imaging of s.c. GPA33(+) tumors was possible for PRITwith
177Lu-DOTA-Bn, suggesting that quantitative imaging com-
bined with therapy is possible (e.g., with QSPECT [36]). In
addition, we demonstrated that serial, noninvasive PET imag-
ing of s.c. GPA33(+) tumors was possible for PRIT with 86Y-
DOTA-Bn. It should be noted that the affinities for C825
binding of yttrium and lutetium are virtually identical and in
the picomolar range. 177Lu has a considerably longer half-life
than 86Y (6.73 days and 14.7 h, respectively). Even so, the
kinetics of rapid localization and long-term retention of theM-
DOTA-Bn favors the use of 86Y because the half-life is long
enough to allow accurate determination of the time course of
uptake and subsequent prolonged clearance of a targeted ther-
apeutic radiolanthanide. Furthermore, the half-life of 86Y is
sufficiently short to not appreciably increase the absorbed
doses to normal organs during 177Lu-based PRIT and could
also allow repeated measurements before each cycle of a frac-
tionated approach. Thus, 86Y is a suitable surrogate diagnostic
for 177Lu. Further, PET imaging is more quantitatively accu-
rate than other nuclear imaging methods such as SPECTwith
177Lu and in general. Finally, 86Y could be used as a
pretherapy tracer for RIT dosimetry with either 90Y or 177Lu
during anti-GPA33 PRIT. 86Y has a complex spectrum, and
radiation exposure is not insignificant. However, in a
theranostic application, in which much larger treatment doses
are anticipated, the gain from its use would outweigh the risk,
because of the potential for improving patient selection and
treatment planning. Also, corrections must be made for opti-
mal reconstruction; notably, in addition to positrons, the large
number of prompt gamma rays emitted by 86Y can interfere
with PET image quantitation, but accuracy can be significant-
ly improved with correction algorithms [37, 38].
During our investigation of anti-GPA33 PRIT, we
made some notable observations regarding opportunities
for improvement of current targeting reagents. First, the
binding affinity of huA33 for its cognate antigen was
reduced when the C825 was attached. Although we were
able to achieve high TIs and apparently prolonged tumor
retention during in vivo PRIT, the in vitro binding affinity
data (Biacore) showed that huA33-C825 showed consid-
erably lower affinity for antigen GPA33 as compared to
parental huA33-IgG. This is consistent with modeling
predictions of the affinity-dependence of tumor uptake,
which indicate that large molecules (e.g., IgGs) are able
to achieve similar uptake levels at much lower affinities in
the 10−8 to 10−6 mol/L Kd range, presumably due to the
slow rate of intravasation allowing repeated binding with-
in the tumor [39 , 40 ] . The C825 a f f in i ty fo r
radiolanthanide Bn DOTA was unaffected. Nonetheless,
we do not rule out the possibility that tumor targeting
could be improved by affinity recovery, as well as by
addressing other issues related to the pharmacokinetics
and biodistribution of the BsAb [41]. These issues are
currently under study. Second, uptake of the M-DOTA-
Bn by antibody prelocalized to tumor was only 10 % of
that predicted on a picomolar basis. We speculate that the
low maximum capacity is likely due to a combination of
factors, including the metabolism of the dextran CA and
subsequent leakage of small DOTA-dextran fragments in-
to the circulation, and the in vivo stability (e.g., proteo-
lytic) of the DOTA-binding scFv C825. Future studies
will include alternative CA with improved serum stability,
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to reduce the likelihood of small DOTA hapten fragment
leakage into the circulation following hepatic metabolism
as well as using no-carrier-added formulations of 177Lu-
DOTA-Bn, which could offer an improvement of about
three-fold in 177Lu-specific activity (from about 1,
110 GBq/mg to a theoretical specific activity of 4,
033 GBq/mg Lu).
Successful development of a theranostic PRIT ap-
proach in CRC would meet an unmet need for cancer
detection and management, and a platform-based PRIT
paradigm may indeed be feasible using a variety of IgG-
C825 antibodies targeting human cancers. Our previous
investigations of PRIT, including PRIT of neuroblastoma
based on hu3F8-C825 [18], support the practicality of the
platform concept. For one thing, once optimal clearing
reagents and C825 haptens have been developed, these
same reagents can be used as a component of theranostic
approaches in combination with bifunctional antibody
forms of antigen specificities for a broad spectrum of hu-
man tumors. In addition, direct applicability to most hu-
man tumors provides several possible advantages. First,
radiation effects at high absorbed doses have wholly dis-
tinct patterns of resistance from that of current drugs and
(nonradioactive) antibodies, and we therefore expect com-
plementary effects to current drugs. Second, utilizing a
theranostic approach, both diagnostic and therapeutic se-
lection information can be obtained at Btracer doses.^ This
permits optimized patient dosing and the avoidance of
treatment in patients whose tumors are not targeted by
the antibody and who are therefore not likely to benefit
from this treatment because of low tumor radiation dose
or high dose to critical organs such as the kidney and gut.
Furthermore, in this study we characterized the impor-
tance of the mass used in the three targeting steps and
their effect on tumor localization and normal organ up-
take. Similar data will need to be obtained in patients.
To optimize these dose-seeking studies a modeling ap-
proach may be utilized [42]. Finally, a modular therapy
in which the radioactivity is separated from the antibody
infusion is appealing in a clinical setting, leading to an
inherently multidisciplinary approach. For example, pa-
tient management and radiation safety measures are
simplified.
Conclusion
Using a three-step PRIT protocol with the anti-GPA33/anti-
DOTA(metal) BsAb huA33-C825, a dextran-based CA, and
177Lu-DOTA-Bn, mice with established s.c. SW1222 human
CRC xenografts were treated with 177Lu-DOTA-Bn adminis-
tered activities as high as 111.0 MBq without demonstrable
radiotoxicity to normal tissues including bone marrow and
kidney. Fractionated administered activities were significantly
more effective than equivalent single activities in terms of
tumor response. In addition, serial noninvasive PET imaging
with pretargeted 86Y-DOTA-Bn was successfully demonstrat-
ed to be a basis for optimizing diagnosis and dosimetry of
pretargeted 177Lu-DOTA-Bn and 86Y-DOTA-Bn for PRIT in
a murine model of human CRC.
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